Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Therapy and aiTBS for Treatment-Resistant Depression
NCT06132178Phase 2Recruiting
- Sponsor
- University of Texas at Austin
- Start
- Jan 2025
- Primary completion
- Dec 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), sponsored by University of Texas at Austin. Started Jan 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06132178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132178.